Lumos Diagnostics (ASX:LDX) has achieved a commercial milestone, announcing its largest purchase order to date for its flagship FebriDx rapid point-of-care test.
The order, valued at US$1.3 million, comes from the company's exclusive US distributor, PHASE Scientific, and signals a rapid acceleration in the product's commercial rollout across North America.
The deal follows the pivotal US Food and Drug Administration 510(k) clearance and subsequent CLIA waiver granted on March 27.
The regulatory milestones are transformative for Lumos, as the CLIA waiver allows FebriDx to be used in a much broader range of healthcare environments beyond high-complexity labs.
By enabling use in urgent care centres and primary care settings, the addressable market for the diagnostic tool has expanded roughly 15-fold, unlocking an estimated market opportunity exceeding US$1 billion.
Lumos CEO Doug Ward noted that the immediacy of this order serves as a powerful validation of the commercial demand for FebriDx in the United States.
As healthcare providers seek more efficient ways to manage patient care at the point of clinical contact, Lumos is positioned to support PHASE Scientific in driving widespread adoption.
The partnership aims to integrate the technology into the frontline of the US medical infrastructure.
At the time of reporting, Lumos Diagnostics' share price was $0.24.